miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma

Approximately 20–30% of patients with metastatic renal cell carcinoma (mRCC) in first-line treatment with tyrosine kinase inhibitors (TKIs) do not respond due to primary resistance to this drug. At present, suitable robust biomarkers for prediction of a response are not available. Therefore, the aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ralla, Bernhard, Busch, Jonas, Flörcken, Anne, Westermann, Jörg, Zhao, Zhongwei, Kilic, Ergin, Weickmann, Sabine, Jung, Monika, Fendler, Annika, Jung, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162741/
https://www.ncbi.nlm.nih.gov/pubmed/30201928
http://dx.doi.org/10.3390/cancers10090321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162741/
https://www.ncbi.nlm.nih.gov/pubmed/30201928
http://dx.doi.org/10.3390/cancers10090321

Ejemplares similares